This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vainionpää, R Articles by Hyypiä, T Search for Related Content PubMed PubMed Citation Articles by Vainionpää, R Articles by Hyypiä, T

 Previous Article

Clin Microbiol Rev. 1994 April; 7(2): 265-275

Biology of parainfluenza viruses.

R Vainionpää and T Hyypiä

Department of Virology, University of Turku, Finland.

SUMMARY

Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, especially in infants and children. PIV1, PIV2, and PIV3 are second only to respiratory syncytial virus as a cause of croup in young children. Although some clinical symptoms are typical of PIVs, etiologic diagnosis always requires detection of infectious virus, viral components, or an antibody response. PIVs are typical paramyxoviruses, causing a syncytial cytopathic effect in cell cultures; virus growth can be confirmed either by hemadsorption or by using immunological reagents. Currently, PIV is most often diagnosed by demonstrating viral antigens in clinical specimens by rapid and highly sensitive immunoassays. More recently, PCR has been used for the detection of PIVs. Serological diagnosis is made by detecting a rising titer of immunoglobulin G or by demonstrating immunoglobulin M antibodies. PIVs infect species other than humans, and animal models are used to study the pathogenesis of PIV infections and to test candidate vaccines. Accumulating knowledge on the molecular structure and mechanisms of replication of PIVs has accelerated research on prevention and treatment. Several strategies for vaccine development, such as the use of live attenuated, inactivated, recombinant, and subunit vaccines, have been investigated, and it may become possible to prevent PIV infections in the near future.

---

Clin Microbiol Rev. 1994 April; 7(2): 265-275

This article has been cited by other articles:

• Roger, T., Bresser, P., Snoek, M., van der Sluijs, K., van den Berg, A., Nijhuis, M., Jansen, H. M., Lutter, R. (2004). Exaggerated IL-8 and IL-6 responses to TNF-{alpha} by parainfluenza virus type 4-infected NCI-H292 cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 287: L1048-L1055 [Abstract] [Full Text]  
• Liolios, L., Jenney, A., Spelman, D., Kotsimbos, T., Catton, M., Wesselingh, S. (2001). Comparison of a Multiplex Reverse Transcription-PCR-Enzyme Hybridization Assay with Conventional Viral Culture and Immunofluorescence Techniques for the Detection of Seven Viral Respiratory Pathogens. J. Clin. Microbiol. 39: 2779-2783 [Abstract] [Full Text]  
• Yao, Q., Compans, R. W. (2000). Filamentous particle formation by human parainfluenza virus type 2. J. Gen. Virol. 81: 1305-1312 [Abstract] [Full Text]  
• Aguilar, J. C., Pérez-Breña, M. P., García, M. L., Cruz, N., Erdman, D. D., Echevarría, J. E. (2000). Detection and Identification of Human Parainfluenza Viruses 1, 2, 3, and 4 in Clinical Samples of Pediatric Patients by Multiplex Reverse Transcription-PCR. J. Clin. Microbiol. 38: 1191-1195 [Abstract] [Full Text]  
• Byrappa, S, Gupta, K. (1999). Human parainfluenza virus type 1 phosphoprotein is constitutively phosphorylated at Ser-120 and Ser-184. J. Gen. Virol. 80: 1199-1209 [Abstract]  
• Mansell, A. L., Mark, E. J. (1996). Case 31-1996- An 18-Month-Old Immunosuppressed Boy with Bilateral Pulmonary Infiltrates. NEJM 335: 1133-1140 [Full Text]